Company News
-
Snibe received CE certificate (List A) for MAGLUMI HBsAg (CLIA) Assay
Release Date：2022-04-01
Snibe received the CE certificate (List A) for MAGLUMI® HBsAg (CLIA) assay On March 11, 2022. It further proves the high reliability of the quality and performance of Snibe products, as well as a verification of Snibe’s leading position in the field of chemiluminescence. -
Snibe SARS-COV-2 tests accurately detect Omicron variant
View Count：2214 Release Date：2021-12-03
Based on assessment of sequences and bioinformatics analysis, we confirm that Snibe’s assays for detection of the SARS-CoV-2 virus in the table below are effective in detecting SARS-CoV-2 variants reported by WHO including B.1.1.529 (Omicron), B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), C.37 (Lambda), B.1.617.1 (Kappa), etc. -
Snibe announced a global strategic cooperation with Thermo Fisher Scientific
View Count：11849 Release Date：2019-08-31
From August 29th to 31st, 2019, the 15th National Congress of Laboratory Medicine (NCLM 2019), hosted by Chinese Medical Association and Chinese Society of Laboratory Medicine, was held at Suzhou International Expo Centre. -
Snibe receives the 1st IVDR CE certificate of CLIA product in Asia
View Count：1076 Release Date：2020-12-16
On December 15, 2020, Snibe's MAGLUMI® TSH assay and MAGLUMI® CA 19-9 assay were certified the IVDR CE Certification by TÜV SÜD Product Service GmbH an EU Notified Body, making Snibe one of the first IVDR CE-certified manufacturers for CLIA products in Asia. -
MAGLUMI HIV Ab/Ag Combi CLIA Assay (4th-Generation) is CE Marked (List A) - A good quality solution to the early diagnosis of HIV infection
View Count：4622 Release Date：2021-04-14
Shenzhen, China, 14 April 2021 - Snibe received the approval of the CE certificate (List A) for the HIV Ab/Ag Chemiluminescence Immunoassay (CLIA) assay. -
Snibe Launches Lab-based SARS-CoV-2 Antigen Quantitative Detection Kits with CE Mark
View Count：6500 Release Date：2021-03-05
Shenzhen, China, 22nd February, 2021-Snibe launches MAGLUMI® SARS-CoV-2 Ag with CE mark, which is a reliable chemiluminescence immunoassay solution for the quantitative detection of nucleocapsid antigens of SARS-CoV-2 from suspected COVID-19 patients. Besides, the SARS-CoV-2 Antigen Test aids to the early detection of SARS-CoV-2 virus from acute COVID-19 infection.